Sex steroids in osteoporosis: The physiological approach to prevention and treatment;Hormonas sexuais e osteoporose: A perspectiva fisiologica da prevencao e terapeutica

Acta Medica Portuguesa

Volumn 10, Issue 10, 1997, Pages 689-695

  Da Silva, José António P ^a   Porto, Armando ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; CORTICOSTEROID; ESTROGEN; GESTAGEN; SEX HORMONE; TESTOSTERONE;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; ESTROGEN DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS;

ANDROGENS; BONE AND BONES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; SEX FACTORS;

EID: 0031411384     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. DICK IM, PRINCE RL, KELLY JJ, HO KKY: Oestrogen effects on calcitriol levels in post-menopausal women: a comparison of oral versus transdermal administration. Clin Endocrinol 1995; 43: 219-24.
2. MANOLAGAS SC, BELLIDO T, JILKA RL, Sex steroids, cytokines and the bone marrow: new concepts on the pathogenesis of osteoporosis. Ciba Foundation Symposium 1995;191:187-202.
3. HARMS HM, NEUBAUERE O, KAYSER C et al: Pulse amplitude and frequency modulation of parathyroid hormone in early postmenopausal women before and on hormone replacement therapy. J Clin Endocrinol Metab 1994;78:48-52
4. RIGGS BL, O'FALLON, LANE A et al: Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 1994;9:265-75.
5. GRADY D, RUBIN SM, PETITTI DB et al: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;17:1016-37.
6. a Edição, 1994:148-67.
7. NAESSEN T, LINDMARK B, LARSEN HC: Better neuromuscular balance function in estrogen users. (Abstract). World Congress of Osteoporosis, 1996
8. ARMAMENTO-VILLAREAL R, CIVITELLI R; Estrogen action on the bone mass of postmenopausal women is dependent on body mass and initial bone density. J Clin Endocrinol Metab 1995;80:776-82
9. CAULEY JA, SEELEY DG, ENSRUD K, ETTINGER B, BLACK D, CUMMINGS SR: Estrogen replacement therapy and fractures in older women. Ann Int Med 1995;122:9-16.
10. LYNDSAY R, HART DM, AITKEN JM, MACDONALD EB, ANDERSON JB, CLARKE AC: Long term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment- Lancet 1976;1:1038-41.
11. MARX CW, DAILEY GE 3RD, CHENEY C, VINT VC 2D, MUCHMORE DB: Do estrogens improve bone mineral density in osteoporotic women over age 65? J Bone Miner Res 1992;7:1275-9.
12. ETTINGER B, GENANT HK, CANN CE: Long-term estrogen replacement therapy prevents bone loss and fractures Ann Int Med 1985; 102: 319-24
13. FELSON DT, ZHANG Y, HANNON MT, KIEL DP, WILSON PW, ANDERSON JJ: The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
14. MANSON JE, TOSTESON H, RIDKER PM et al: The primary prevention of myocardial infarction. N Engl J Med 1992;326:1406-16.
15. SPECTOR TD, HALL GM, MCCLOSKEY EV, KANIS JA: Risk of vertebral fracture in women with rheumatoid arthritis. Br Med J 1993;306:558.
16. COOPER C, WICKHAM C: Rheumatoid Arthritis, corticosteroid therapy and hip fracture. In Christiansen C e Overgaard K, eds. Osteoporosis 1990. Copenhaga, Osteopress, 1990.
17. HALL GM, DANIELS M, DOYLE DV, SPECTOR TD: Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37: 1499-505.
18. SAMBROOK P, BIRMINGHAM J, CHAMPION D et al: Postmenopausal bone loss in rheumatoid arthritis: effect of estrogens and androgens. J Rheumatol 1992;19:357-61.
19. van der BRINK HR, LEMS WF, VAN EVERDRINGEN AA, BIJLSMA JWJ: Adjuvant oestrogen treatment increases bone density in post-meopausal women with rheumatoid arthritis. Ann Rheum Dis 1993;52:302-5.
20. LUKERT BP, JOHNSON BE, ROBINSON RG: Estrogen and progesterone replacement therapy reduces glncocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-9.
21. DEQUEKER J, WESTHOVENS R. Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and us prophylaxis and treatment: bones of contention (ed.). J Rheumatol 1995;22:1013-9.
22. HALL GM, DANIELS M, HUSKISSON EC, SPECTOR TD: A randomized controlled trial of hormone replacement therapy in postmenopausal rheumatoid arthritis. Ann Rheum Dis 1994;53:112-6.
23. MACDONALD AG, MURPHY EA, CAPELL HA, BANKOWSKA UZ, RALSTON SH: Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 1994;53:54-7.
24. van den BRINK HR, VAN EVERDRINGEN A, VAN WIJK MJG, JACOBS JWG, BIJLSMA JWJ: Adjuvant estrogen therapy has no effect on disease activity in postmenopausal women with active rheumatoid arthritis. Arthritis Rheum 1992;35:S202.
25. ANDERSON F, FRANCIS R, HINDMARSH P, FALL C, COOPER C Serum oestradiol in osteoporotic and normal men is related to bone mineral sdensity. (Abstract) World Congress of Osteoporosis, 1996
26. SLEMENDA C, LONGCOPE C, HUI S, ZHOU L, JOHNSTON CC: Estrogens but not androgens are positively associated with bone mass in older men. (Abstract). World Congress of Osteoporosis, 1996.
27. BERNECKER PM, WILLVONSEDER R, RESCH H: Sex hormone levels and parameters of bone metabolism in osteoporotic men. (Abstract). World Congress of Osteoporosis, 1996.
28. SCHWELKERT H-U, WOLF L, ROMALO G: Oestrogen fromation from androstenedione in human bone. Clin Endocrinol 1995;43: 37-42.
29. DEQUEKER J, DEMUYLDER E, FERIN J: The effect of longterm lynestrenol treatment on bone mass in cycling women. Contraception 1977;15:717-23.
30. LOBO RA, MCCORMICK W, SINGER F: Depo-medroxyprogesterone acetate compared with conjugated estrogens for treatment of postmenopausal osteoporosis. Obst Gynecol 1984;63:1-5.
31. CHRISTIANSEN C, NILAS L, RIIS BJ, RODBRO P, DEFTOS LJ: Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 1985;2:800-1.
32. PRIOR JC. Progesterone as a bone-trophic hormone. Endocr Reviews 1990;11:386-98.
33. GENANT H, SYMONS J, ROWAN J, SPEROFF L: The effect of continuous HRT on spinal trabecular bone mineral density. (Abstract). World Congress of Osteoporo, 1996.
34. TLUSTOCOWICZ W, STASZEWSKI A, JASTRZAB L, KALINSKI A: 17β-estradiol and 17β-estradiol combined with medroxyprogesterone in postmenopausal osteoporosis treatment - comparison of efficacy and influence on serum lipids. (Abstract). World Congress of Osteoporosis, 1996.
35. VALK DE ROO GW, NETELENBOS JC, PETERS-MULLER E et al: Effects of continuously combined replacement therapy on the biochemical markers of bone turnover. (Abstract). World Congress of Osteoporosis, 1996.
36. PRIOR JC, VIGNA YM, BARR SI, REXWORTHY C, LENTLE BC Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual disturbances.. Am J Med 1994;96:521-30.
37. CUNDY T, CORNISH J, EVANS MC, HOLMES H, REID IR: Spinal bone density in women using depot medroxyprogesterone contraception. (Abstract). World Congress of Osteoporosis, 1996.
38. GRECU E, GORDAN G, SIMMONS R: Medroxyprogesterone acetate as an antagonist of adverse glucocorticoid effects on clacium metabolism in man. In Christiansen C, Johansen JS e Riis BJ, eds, Osteoporosis 1987. Copenhaga. Osteopress 1987.
39. STANLEY HL, SCHMITT BP, POSES RM, DEISS WP: Does hypogonadism contribute to the ocurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991;39:766-71.
40. SEEMAN E, MELTON LJ III: Risk factors for Osteoporosis in men. Am J Med 1983;75:977-83.
41. TALALAJ M, DEBSKI K, MARCINOWSKA-SUCHOWIERSKA E, WITESKA A, BOROWICZ J: Effects of artificial andropause on calcium-phosphate homeostasis and bone mass in patients with prostatic carcinoma. (Abstract). World Congress of Osteoporosis, 1996.
42. DEVOGELAER JP, DE COOMAN S. NAGANT DE DEUXCHAISNES C: Low bone mass in hypogonadal males. Effect of testesterone substitution therapy, a densitometric study. Maturitas 1992;15: 1 17-23.
43. KASRA M, GRYNPAS MD: The effects of androgens on the mechanical properties of primate bone. Bone 1995;17:265-70.
44. ISAIA G, MUSSETTA M, PECCHIO F, SCIOLLA A, DI STEFANO M, MOLINATTI GM: Effect of testosterone on bone in hypogonadal males. Matuntas 1992;15:47-51.
45. HALL GM, LARBRE JP, SPECTOR TD, PERRY LA, DA SILVA JAP: A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 1996;35:568-73.
46. COLVARD D, ERKSEN E, KEETING P et al: Identification of androgen receptors in normal human osteoblast-like cells. Proc Nal Acad Sci 1989; 86: 854-7.
47. KASPERK CH, WERGEDAL JE, FARLEY FR et al: Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989;124:1576-8.
48. SLEMENDA C, LONGCOPE C, PEACOCK M, HUI S, JOHNSTON CC: Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest 1996;97;14-21.
49. NORDIN BEC, ROBERTSON A, SEAMARK RF et al: The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab 1985;60:651-6.
50. GASPERINO J: Androgenic regulation of bone mass in women. Clin Orthop Rel Res 1995;311:278-86.
51. SLEMENDA CW, HUI SL, LONGCOPE CL, JOHNSTON CC: Sex steroids and bone mass. A study of change about the time of menopause. J Clin Invest 1987;80:1261-9.
52. DIXON JE, RODIN A, MURBY B et al: Bone mass in hirsute women with androgen excess. Clin Endocrinol 1989;30:271-7.
53. DAVIS SR, MCCLOUD P, STRAUSS BJG, BURGER H: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
54. RAISZ LG, WIITA B, ARTIS A et al: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996;81:37-43.
55. GEUSENS P, DEQUEKER J: Long-term effect of nandrolone decanoate, lalfa-hydroxy vitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic Osteoporosis. a double-blind controlled study. Bone Min 1986;1:347-57.
56. NEED AG, HOROWITZ M, BRIDGES A, MORRIS HA, NORDIN BEC: Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Arch Int Med 1989;149:57-60
57. METS T, VERBRUGGEN LA, LOUIS O, SMITZ J, VERHAE-VERBEKE I, KAUF L: Treatment of severe Osteoporosis in the very old. (Abstract). World Congress of Osteoporosis, 1996.